VivoSeq
Other

RAS Mutation

1

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

RAS Mutation is an early-stage landscape with 1 program across 2 companies. The most active players are Adlai Nortye Biopharma Co., Ltd., AstraZeneca.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Adlai Nortye Biopharma Co., Ltd.

2 programs

Phase 1AstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Intravenous AN4035

Adlai Nortye Biopharma Co., Ltd.

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

7

clinical trials

Completed2 · 29%
Terminated2 · 29%
Not yet recruiting2 · 29%
Recruiting1 · 14%

Clinical Trials

Trial Activity

7 trials

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations
Recruiting·NN.N. Petrov National Medical Research Center of Oncology·Phase 2·NCT06229340·20 enrolled
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
Not yet recruiting·LLudwig-Maximilians - University of Munich·Phase 2·NCT04034173·120 enrolled
A Multi-center, Open-label, Phase I Study Evaluating Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AN4035 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations and Enriched for CEACAM5 Expression
Not yet recruiting·AAdlai Nortye Biopharma Co., Ltd.·Phase 1·NCT07686445·288 enrolled
Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations
Completed·VVejle Hospital·Phase 2·NCT00792363·32 enrolled
AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00890825·88 enrolled
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Terminated·National Cancer Institute (NCI)·Phase 2·NCT04566133·2 enrolled
Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS
Terminated·SSpanish Lung Cancer Group·Phase 2·NCT03496766·9 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)